Abstract: The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a Crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of miRNA in a sample from the patient, wherein said miRNA are miR15a, miR26a, miR29a, miR29b, miR30c, miR126*, miR127-3p, miR-142-3p, miR-142-5p, miR-146a, miR-146b-5p, miR150, miR-181d, miR-182, miR185, miR196a, miR199a-3p, miR199a-5p, miR199b-5p, miR-203, miR223, miR-299-5p, miR320a, miR324-3p, miR-328.

Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).

Abstract: The present invention provides combinations of antibodies for use in the treatment or the prevention of HCV infection. In particular, combinations are provided that comprise at least one anti-HCV envelope antibody and at least one anti-HCV receptor antibody, wherein the anti-HCV-envelope antibody and anti-HCV-receptor antibody act in a highly synergistic manner to inhibit HCV entry into susceptible cells. Also provided are pharmaceutical compositions and kits comprising such combinations and methods of using these compositions and kits for treating or preventing HCV infection.

Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.

Abstract: The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM I-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.

Abstract: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.

Abstract: The invention relates to a mutated cell such as a bacteria or yeast in which the thyA gene coding thymidylate synthase includes a nonsense codon, preferably the amber codon, said nonsense codon replacing a codon coding an amino acid and inducing the interruption of thyA gene translation and the auxotrophy of the cell for the thymidine. Advantageously, the endA gene coding the endonuclease 1 and/or the recA gene coding the recombinase is inactivated in said mutated cell. The invention also relates to an expression plasmid including a transgene and a sequence of a suppressing ARM structural gene containing an anticodon that can be paired with the nonsense codon of the thyA gene and is specific of an amino acid capable of restoring the translation of the mutated thyA gene and thereby obtaining a protein of the wild or mutated type having a thymidylate synthase activity. The invention also relates to a method for the multiplication of the expression plasmid.

Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.

Abstract: The invention relates to a method of treatment of a human patient suffering from Myeloid Neoplasias, comprising administrating a therapeutically effective amount of acadesine, acadesine precursors or acadesine derivatives.

Abstract: The present invention relates to a recombinant vector for expressing and secreting, by a propionibacterium, one or more amino acid sequences of interest, wherein said vector comprises at least: under the control of at least one suitable promoter, at least one nucleotide sequence coding for a propionibacteria signal peptide and, in translational fusion with said nucleotide sequence, one or more nucleotide sequences coding for said amino acid sequence or sequences of interest. The invention further relates to the uses of such a vector in the pharmaceutical field or for the large-scale production of peptides or proteins of interest.

Abstract: The application relates to antibodies which recognize the AviTag™ peptide of sequence MSGLNDIFEAQKIEWHE (SEQ ID No. 1) and to fragments thereof which recognize SEQ ID No. 1, wherein said antibodies or said fragments thereof recognize polypeptides containing SEQ ID No. 1 at their NH2 terminus and polypeptides containing SEQ ID No. 1 at their COOH terminus. The application further relates to a method for sorting target cells presenting on their surface a surface marker from a mixed cell population comprising the steps of: a) incubating said mixed cell population with a tagged adapter which binds to said surface marker of said target cells, wherein said adapter is bound to an antibody which recognizes said tag, and wherein said antibody is immobilized on a solid support. b) collecting said target cells.

Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.

Abstract: The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as Giardia parasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.

Abstract: Proteins having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or fragments of said sequences are provided. The protein fragments are represented by the sequences of SEQ ID NO: 2q, q varying from 3 to 36, and the sequences of SEQ ID NO: 185 to SEQ ID NO: 209. Nucleotide sequences coding for said proteins are also provided.

Abstract: The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy.

Abstract: The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator <eq.metformin or troglizazone>.

Abstract: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.

Abstract: The invention relates to a device for transiently contacting at least one unit for capturing biological targets with a body fluid containing them, a method for recovering the captured targets for analysis, and a system for contacting and recovering a capture substrate included in said unit. The invention relates to samples obtained in particular in vivo from body fluids of the human body, e.g. circulating body fluids, said fluids possibly containing, as targets, proteins, oligonucleotides such as RNA or DNA, antibodies, enzymes or cells.